Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Anastasios G. Konstas, Leopold Schmetterer, Vital P. Costa, Gábor Holló, Andreas Katsanos, Philippe Denis, Luciano Quaranta, Murat Irkec, Miguel A. Castejón, Miguel A. Teus & Alan L. Robin. (2020) Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opinion on Drug Safety 19:11, pages 1445-1460.
Read now
Read now
Lindsay Machen, Reza Razeghinejad & Jonathan S. Myers. (2020) Fixed-combination topical anti-hypertensive ophthalmic agents. Expert Opinion on Pharmacotherapy 21:10, pages 1269-1282.
Read now
Read now
Nathan M Radcliffe. (2014) The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clinical Ophthalmology 8, pages 2541-2549.
Read now
Read now
Elad Moisseiev, Shimon Kurtz, Moshe Lazar & Gabi Shemesh. (2013) Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily. Clinical Ophthalmology 7, pages 1269-1273.
Read now
Read now
L. Jay Katz, Steven H. Rauchman, Andrew J. Cottingham$suffix/text()$suffix/text(), Steven T. Simmons, Julia M. Williams, Rhett M. Schiffman & David A. Hollander. (2012) Fixed-combination brimonidine–timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Current Medical Research and Opinion 28:5, pages 781-788.
Read now
Read now
Marina Papadia, Alessandro Bagnis, Riccardo Scotto & Carlo E Traverso. (2011) Tafluprost for glaucoma. Expert Opinion on Pharmacotherapy 12:15, pages 2393-2401.
Read now
Read now
Nurşen Yüksel, Mustafa Gök, Özgül Altıntaş & Yusuf Çağlar. (2011) Diurnal Intraocular Pressure Efficacy of the Timolol-Brimonidine Fixed Combination and the Timolol-Dorzolamide Fixed Combination as a First Choice Therapy in Patients with Pseudoexfoliation Glaucoma. Current Eye Research 36:9, pages 804-808.
Read now
Read now
Eve J Higginbotham. (2010) Considerations in glaucoma therapy: fixed combinations versus their component medications. Clinical Ophthalmology 4, pages 1-9.
Read now
Read now
M Reza Razeghinejad, Andrea K Sawchyn & L Jay Katz. (2010) Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opinion on Pharmacotherapy 11:6, pages 959-968.
Read now
Read now
Anna Galanopoulos & Ivan Goldberg. (2009) Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clinical Ophthalmology 3, pages 117-122.
Read now
Read now
Articles from other publishers (19)
Nathan M. Radcliffe, Manjool Shah & Thomas W. Samuelson. (2023) Challenging the "Topical Medications-First” Approach to Glaucoma: A Treatment Paradigm in Evolution. Ophthalmology and Therapy 12:6, pages 2823-2839.
Crossref
Crossref
José Alvaro P. Gomes, Dimitri T. Azar, Christophe Baudouin, Etty Bitton, Wei Chen, Farhad Hafezi, Pedram Hamrah, Ruth E. Hogg, Jutta Horwath-Winter, Georgios A. Kontadakis, Jodhbir S. Mehta, Elisabeth M. Messmer, Victor L. Perez, David Zadok & Mark D.P. Willcox. (2023) TFOS Lifestyle: Impact of elective medications and procedures on the ocular surface. The Ocular Surface 29, pages 331-385.
Crossref
Crossref
Sapna Sinha, Wesam Shamseldin Shalaby, Wendy W. Liu, Reza Razeghinejad & L. Jay Katz. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
612
661
.
Po-Han Yeh, Yu-Chun Cheng, Shian-Sen Shie, Yung-Sung Lee, Su-Chin Shen, Henry Shen-Lih Chen, Wei-Chi Wu & Wei-Wen Su. (2021) Brimonidine related acute follicular conjunctivitis. Medicine 100:29, pages e26724.
Crossref
Crossref
Prin Rojanapongpun & Visanee Tantisevi. 2021. Primary Angle Closure Glaucoma (PACG). Primary Angle Closure Glaucoma (PACG)
31
44
.
Eun Jung ParkYeoun Sook Chun. (2018) Comparison of Allergy Prevalence between Brimonidine/Timolol Fixed Combination and 0.15% Brimonidine in Glaucoma Patients. Journal of the Korean Ophthalmological Society 59:5, pages 451.
Crossref
Crossref
Curt Hartleben, Juan Camilo Parra, Amy Batoosingh, Paula Bernstein & Margot Goodkin. (2017) A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure. Journal of Ophthalmology 2017, pages 1-9.
Crossref
Crossref
Joon Mo Kim, Tae-Woo Kim, Chan Yun Kim, Hwang Ki Kim & Ki Ho Park. (2015) Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients. Japanese Journal of Ophthalmology 60:1, pages 20-26.
Crossref
Crossref
Alex S. Huang, Lilit Minasyan & Robert N. Weinreb. 2017. Pharmacologic Therapy of Ocular Disease. Pharmacologic Therapy of Ocular Disease
181
207
.
Adam C Reynolds. 2015. Glaucoma. Glaucoma
566
576
.
María Alejandra Carrasco, Bernardo Ariel Schlaen & Jorge Oscar Zárate. (2012) Brimonidine–timolol fixed combination induced granulomatous inflammation of the eye. International Ophthalmology 33:5, pages 557-560.
Crossref
Crossref
AARON D. GRANT & SOPHIA M. CHUNG. (2013) The Eye in Pregnancy. Clinical Obstetrics & Gynecology 56:2, pages 397-412.
Crossref
Crossref
Alessandro Bagnis, Marina Papadia, Riccardo Scotto & Carlo E. Traverso. (2011) Antiglaucoma drugs: The role of preservative-free formulations. Saudi Journal of Ophthalmology 25:4, pages 389-394.
Crossref
Crossref
Stella Arthur & Louis B. Cantor. (2011) Update on the role of alpha-agonists in glaucoma management. Experimental Eye Research 93:3, pages 271-283.
Crossref
Crossref
Elena S. Novitskaya, Simon J. Dean, Jennifer P. Craig & Anton B. Alexandroff. (2011) Current dilemmas and controversies in allergic contact dermatitis to ophthalmic medications. Clinics in Dermatology 29:3, pages 295-299.
Crossref
Crossref
George L. Spaeth, Paula Bernstein, Joseph Caprioli & Rhett M. Schiffman. (2011) Control of Intraocular Pressure and Fluctuation With Fixed-Combination Brimonidine–Timolol Versus Brimonidine or Timolol Monotherapy. American Journal of Ophthalmology 151:1, pages 93-99.e4.
Crossref
Crossref
Michael Sullivan-MeeDenise PensylBrooks AlldredgeKathy HalversonGretchen GerhardtClifford Qualls. (2010) Brimonidine Hypersensitivity when Switching Between 0.2% and 0.15% Formulations. Journal of Ocular Pharmacology and Therapeutics 26:4, pages 355-360.
Crossref
Crossref
Quang H. NguyenMelissa Earl. (2009) Fixed-Combination Brimonidine/Timolol as Adjunctive Therapy to a Prostaglandin Analog: A 3-Month, Open-Label, Replacement Study in Glaucoma Patients. Journal of Ocular Pharmacology and Therapeutics 25:6, pages 541-544.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Allergy & Clinical Immunology 9:5, pages 482-488.
Crossref
Crossref